Tag: CYP2C19

A Gut Bug, Genetics and Treating Serious Stomach Diseases

By Bertram Koelsch Do you know the bacteria H. pylori? Well, H. pylori may already know you. H. pylori can be found in the stomach of 30-40 percent of people in the US and 70 percent or more of people in developing regions. Indeed, humans have a long-standing and intimate relationship with these ...

Read more

The Debate Over Clopidogrel Continues

In December a new study created quite a stir in the already-volatile clopidogrel research community. Clopidogrel (trade names Plavix®) is a commonly prescribed anti-clotting drug. It is inactive in the body until a protein encoded by the gene CYP2C19 converts the drug to its active form. Some people are able ...

Read more

FDA Adds Boxed Warning to Plavix Label to Highlight Reduced Effectiveness of the Drug In Poor Metabolizers

The U.S. Food and Drug Administration (FDA) has updated the label information for the commonly used anti-clotting medication Plavix® (clopidogrel) to stress to physicians that patients carrying certain genetic variations may not receive the full benefit from the drug. Plavix reduces the chance a harmful ...

Read more

Medco to Include Genetics in Comparison of Anti-Clotting Drug Effectiveness

Medco Health Solutions, Inc., announced this week that it will conduct a clinical trial to assess whether clopidogrel bisulfate (Plavix®, Bristol-Myers Squibb and Sanofi-aventis) is just as effective as the newer drug prasugrel (Effient™, Eli Lilly and Company) in people who lack a genetic variation that ...

Read more

SNPwatch: Genetic Variants May Reduce Ability of Anti-Clotting Drug Clopidogrel to Prevent a Second Heart Attack

SNPwatch gives you the latest news about research linking various traits and conditions to individual genetic variations. These studies are exciting because they offer a glimpse into how genetics may affect our bodies and health; but in most cases, more work is needed before this research can provide ...

Read more

Return to top